Pharmaceuticals

Pharscin Pharma

Pharscin Pharma released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 211.85 M, actual EPS CNY 0.0785

Pharscin Pharma to Release FY2026 Q1 Earnings on April 30 After-Market BJT

Pharscin Pharma released FY2025 earnings on April 23 Pre-Market (BJT), actual revenue CNY 827.14 M, actual EPS CNY 0.1559

Pharscin Pharma released FY2025 Q4 earnings on April 23 Pre-Market (BJT), actual revenue CNY 201.23 M, actual EPS CNY -0.0176

Pharscin Pharma to Release FY2025 Annual Earnings on April 24, 2026 Pre-Market (BJT)

Pharscin Pharma released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue CNY 184M, actual EPS CNY 0.0443

Pharscin Pharma released FY2025 9 Months Earnings on October 28 Pre-Market (BJT), Actual Revenue CNY 625.91 M, Actual EPS CNY 0.1734

Pharscin Pharma to Release FY2025 Q3 Earnings on October 29 Pre-Market BJT

Pharscin Pharma released FY2025 Semi-Annual Earnings on August 21 After-Market (BJT), Actual Revenue: CNY 441.91M, Actual EPS: CNY 0.1292

Pharscin Pharma released FY2025 Q2 earnings on August 21 After-Market BJT, actual revenue CNY 202.97 M, actual EPS CNY 0.0325

Pharscin Pharma to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Huasan Pharmaceutical Pays Additional Taxes and Penalties

Controlling Shareholder of Huasen Pharmaceutical Reduced Shares by 1%

Huasen Pharmaceutical Conducts Block Trade

Huasan Pharmaceutical experiences block trades with 378,000 hands traded in the past three months

Huasan Pharmaceutical Experiences 19 Large Transactions

Huasan Pharmaceutical's CX001 Extended-Release Tablets Approved for Clinical Trials

Huasan Pharmaceutical Conducted a Block Trade

Huasan Pharmaceutical Experiences Block Trades and Shareholder Reductions

Huasan Pharmaceutical Had A Block Trade

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Allist

Xingqi Pharmaceutical

Hengrui Pharma

Yunnan Baiyao

Haisco

Asymchem

CR Sanjiu

Salubris

DEEJ

YILING PHARMACEUTICAL

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

002907

Pharscin Pharma announced that it recently received the "Drug Re-registration Approval Notice" for its product, injectable sulbactam-natamycin, issued by the Chongqing Municipal Drug Administration. The drug approval number is valid until October 22, 2030. The re-registration of this product is approved. Since this product has not been produced for a long time, before resuming production, the holder must complete the relevant work according to the requirements of related documents and submit a resumption application to the Municipal Drug Administration. After on-site inspection and passing the quality check of a batch of products, and subsequent two batches of products passing inspection, it can be marketed for sale

Zhitong

Pharscin Pharma: Injectable Sulbactam-Nafcillin has received drug re-registration approval

According to the Zhitong Finance APP, Pharscin Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 626 million yuan, a year-on-year increase of 1.90%. The net profit attributable to shareholders of the listed company was 72.4556 million yuan, a year-on-year decrease of 2.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 52.2035 million yuan, a year-on-year decrease of 13.03%

Pharscin Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 72.4556 million yuan, a year-on-year decrease of 2.84%

Pharscin Pharma responded on the interactive platform on October 23rd, stating that Crizotinib capsules are currently under the patent protection period of the original research company, and they are expected to be available for sale by the end of next year. The sales of the drug are influenced by various factors including industry policies, and the company is currently unable to estimate sales figures

Pharscin Pharma: Crizotinib capsules are expected to be launched for sale by the end of next year

Pharscin Pharma has obtained the drug registration certificate for Crizotinib capsules issued by the National Medical Products Administration. This drug was launched in the Chinese market in 2013 and was included in the medical insurance system in 2018, with over ten years of clinical application experience, primarily used for the treatment of patients with advanced non-small cell lung cancer who are ALK-positive and ROS1-positive

Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules

According to the Zhitong Finance APP, Pharscin Pharma announced that the company recently received a notice from Mr. You Hongtao, a concerted actor of the controlling shareholder, and Shanghai Tiancheng Investment Management Co., Ltd. - Tiancheng Tianli No. 1 Private Securities Investment Fund (referred to as "Tiancheng Tianli No. 1 Fund") regarding the plan to reduce their holdings in the company. The total reduction plan will not exceed 12.5278 million shares, accounting for no more than 3% of the company's total share capital

Pharscin Pharma's controlling shareholder's concerted action parties plan to reduce their holdings by no more than 3%

Pharscin Pharma recently received a re-registration approval notice from the Chongqing Municipal Drug Administration, including 1 chemical raw material and 1 pharmaceutical product. The validity period of the chemical raw material Povidone-Iodine is 24 months, until September 21, 2030; the validity period of the injectable Gabapentin Mesylate is until September 24, 2030. This re-registration will ensure the normal production and sales of the pharmaceutical products and will not have a significant impact on operating performance in the short term

Pharscin Pharma: The company has received the drug re-registration approval notice

According to the Zhitong Finance APP, Pharscin Pharma announced that the company recently received the "Chemical Raw Material Drug Re-registration Approval Notice" for ammonium glycyrrhizinate and the "Drug Re-registration Approval Notice" for sodium ferulate issued by the Chongqing Municipal Drug Administration. Ammonium glycyrrhizinate: raw material drug used for the production of injectable ammonium glycyrrhizinate. Sodium ferulate for injection: used for adjuvant treatment of ischemic cardiovascular and cerebrovascular diseases

Pharscin Pharma received the drug re-registration approval notice

Pharscin Pharma announced that the company has become the marketing authorization holder for Jian'er Xiaoshi Oral Liquid. This medication is a pediatric traditional Chinese medicine suitable for various symptoms in children caused by irregular eating habits. This change will enrich the company's product line, expand the retail market, increase the sales varieties in the pediatric digestive field, and promote the company's sustainable development

Pharscin Pharma: The company has become the holder of the marketing authorization for the Jian'er Xiaoshi oral liquid medication

Pharscin Pharma announced that its controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. has completed its reduction plan, with a total reduction of 12.5278 million shares, accounting for 3.00% of the total share capital. The reduction methods include centralized bidding and block trading, with price ranges of 17.4-19.29 CNY/share and 14.51-16.27 CNY/share, respectively. In addition, senior management personnel Peng Xiaoyan also conducted a small amount of reduction

Pharscin Pharma: Chengdu Dijiang 3.00% reduction completed

Pharscin Pharma announced that the company's drug production license has been changed and has passed the GMP compliance inspection. The newly added products include injectable esomeprazole sodium, suitable for low-risk patients with gastroesophageal reflux disease. The raw material for agomelatine is used to produce agomelatine tablets, with an expected market share of 790 million yuan in 2024

Pharscin Pharma: Company drug production license change and passing GMP compliance inspection

Pharscin Pharma(002907.SZ)

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Pharscin Pharma: Injectable Sulbactam-Nafcillin has received drug re-registration approval

Pharscin Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 72.4556 million yuan, a year-on-year decrease of 2.84%

Pharscin Pharma: Crizotinib capsules are expected to be launched for sale by the end of next year

Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules

Pharscin Pharma's controlling shareholder's concerted action parties plan to reduce their holdings by no more than 3%